Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNT5BF)

Drug Name

4-cycloheptyl-6-propylpyrimidine-2-carbonitrile Drug Info

Synonyms

CHEMBL1085423; 4-cycloheptyl-6-propylpyrimidine-2-carbonitrile; SCHEMBL5796281

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Cathepsin K (CTSK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Odanacatib	DM1EO3G	Osteoporosis	FB83.0	Phase 3	[2]
SAR-114137	DMZ1XR5	Pain	MG30-MG3Z	Phase 1	[3]
VEL-0230	DMDSC63	Rheumatoid arthritis	FA20	Phase 1	[4]
PMID27998201-Compound-12	DM8QZNC	Bone cancer	2B5Z	Patented	[5]
PMID27998201-Compound-5	DMVZ0ND	Chronic obstructive pulmonary disease	CA22	Patented	[5]
PMID27998201-Compound-9	DM1JOZN	Rheumatoid arthritis	FA20	Patented	[5]
PMID25399719-Compound-17	DMRXKJZ	N. A.	N. A.	Patented	[6]
PMID27998201-Compound-15	DMOB8LU	Pain	MG30-MG3Z	Patented	[5]
Oxotetrahydro-2-H-furo[3.2-b]pyrrol-4(5-H)-yl derivative 1	DM1SH5R	Pain	MG30-MG3Z	Patented	[5]
PMID27998201-Compound-8	DMZK0SY	N. A.	N. A.	Patented	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Cathepsin S (CTSS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RG7625	DMDGPKS	Autoimmune disease	4A40-4A45	Phase 2	[7]
SAR-114137	DMZ1XR5	Pain	MG30-MG3Z	Phase 1	[3]
VBY- 891	DMTKPH4	Autoimmune diabetes	5A10	Phase 1	[8]
VBY- 036	DMULRYC	Neuropathic pain	8E43.0	Phase 1	[9]
VBY-129	DM4YIWK	Autoimmune diabetes	5A10	Phase 1	[10]
PMID27998201-Compound-12	DM8QZNC	Bone cancer	2B5Z	Patented	[5]
PMID27998201-Compound-5	DMVZ0ND	Chronic obstructive pulmonary disease	CA22	Patented	[5]
PMID27998201-Compound-9	DM1JOZN	Rheumatoid arthritis	FA20	Patented	[5]
PMID25399719-Compound-17	DMRXKJZ	N. A.	N. A.	Patented	[6]
PMID27998201-Compound-17	DMAZVHJ	Hair loss	ED70	Patented	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Design and optimization of a series of novel 2-cyano-pyrimidines as cathepsin K inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1524-7.
2	A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
3	From laboratory to pilot plant: the solid-state process development of a highly potent cathepsin S/K inhibitor. Eur J Pharm Biopharm. 2013 Apr;83(3):436-48.
4	Discovery and parallel synthesis of a new class of cathepsin K inhibitors. Bioorg Med Chem Lett. 2001 Nov 19;11(22):2951-4.
5	Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
6	An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31.
7	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2353).
9	Clinical pipeline report, company report or official report of ViroBay.
10	Clinical pipeline report, company report or official report of ViroBay.